Drugbank Logo

Search Results

Search for "Ganciclovir" returned 6 results

Showing 1-6 out of 6
DrugBank ID Name Formula Weight
DB01004
DrugCard button for DB01004
Ganciclovir C9H13N5O4 255.2306
Ganciclovir Ganciclovir is a synthetic nucleoside analogue of 2'-deoxyguanosine that inhibits replication of herpes viruses both <i>in vitro</i> and <i>in vivo</i>. Sensitive human viruses include ...
DB01610
DrugCard button for DB01610
Valganciclovir C14H22N6O5 354.3617
After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. Tablet Oral 02245777 DB01610 Approximately 4.08 hours. Increased in patients with renal ...
DB00529
DrugCard button for DB00529
Foscarnet CH3O5P 126.0053
... HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA ...
DB01032
DrugCard button for DB01032
Probenecid C13H19NO4S 285.3590
... Ganciclovir Probenecid increases the effect and toxicity of ganciclovir/valganciclovir Indomethacin Probenecid increases the effect/toxicity of indomethacin Ketorolac Probenecid increases ...
DB00900
DrugCard button for DB00900
Didanosine C10H12N4O3 236.2273
Ganciclovir The antiviral agent increases the effect and toxicity of didanosine Tenofovir Tenofovir increases the effect and toxicity of didanosine Tipranavir Didanosine EC levels may be reduced ...
DB01048
DrugCard button for DB01048
Abacavir C14H18N6O 286.3323
The antiviral response should be closely monitored. Ganciclovir The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Ganciclovir. There ...
Showing 1-6 out of 6

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.